212 related articles for article (PubMed ID: 24324728)
1. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
[TBL] [Abstract][Full Text] [Related]
2. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
3. Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer.
Strand C; Ahlin C; Bendahl PO; Fjällskog ML; Hedenfalk I; Malmström P; Fernö M
Breast Cancer Res Treat; 2012 Jan; 131(1):33-40. PubMed ID: 21331623
[TBL] [Abstract][Full Text] [Related]
4. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.
Janssen EA; Øvestad IT; Skaland I; Søiland H; Gudlaugsson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
Cell Oncol; 2009; 31(5):335-43. PubMed ID: 19759414
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.
Klintman M; Bendahl PO; Grabau D; Lövgren K; Malmström P; Fernö M;
Mod Pathol; 2010 Feb; 23(2):251-9. PubMed ID: 19935641
[TBL] [Abstract][Full Text] [Related]
6. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.
van Steenhoven JEC; Kuijer A; Kornegoor R; van Leeuwen G; van Gorp J; van Dalen T; van Diest PJ
Histopathology; 2020 Oct; 77(4):579-587. PubMed ID: 32557844
[TBL] [Abstract][Full Text] [Related]
7. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
[TBL] [Abstract][Full Text] [Related]
10. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up.
Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I
Breast Cancer Res Treat; 2016 Jun; 157(2):363-371. PubMed ID: 27155668
[TBL] [Abstract][Full Text] [Related]
11. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
Niméus-Malmström E; Koliadi A; Ahlin C; Holmqvist M; Holmberg L; Amini RM; Jirström K; Wärnberg F; Blomqvist C; Fernö M; Fjällskog ML
Int J Cancer; 2010 Aug; 127(4):961-7. PubMed ID: 19957331
[TBL] [Abstract][Full Text] [Related]
12. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
[TBL] [Abstract][Full Text] [Related]
13. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
[TBL] [Abstract][Full Text] [Related]
14. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
15. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer.
Skaland I; Janssen EA; Gudlaugsson E; Hui Ru Guo L; Baak JP
Cell Oncol; 2009; 31(4):261-71. PubMed ID: 19633363
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.
Reyal F; Hajage D; Savignoni A; Feron JG; Bollet MA; Kirova Y; Fourquet A; Pierga JY; Cottu P; Dieras V; Fourchotte V; Laki F; Alran S; Asselain B; Vincent-Salomon A; Sigal-Zafrani B; Sastre-Garau X
PLoS One; 2013; 8(3):e55901. PubMed ID: 23526930
[TBL] [Abstract][Full Text] [Related]
18. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
[TBL] [Abstract][Full Text] [Related]
19. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
